Organon & Co
NYSE:OGN

Watchlist Manager
Organon & Co Logo
Organon & Co
NYSE:OGN
Watchlist
Price: 9.76 USD 0.21% Market Closed
Market Cap: $2.5B

Relative Value

The Relative Value of one OGN stock under the Base Case scenario is 45.75 USD. Compared to the current market price of 9.76 USD, Organon & Co is Undervalued by 79%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

OGN Relative Value
Base Case
45.75 USD
Undervaluation 79%
Relative Value
Price
Worst Case
Base Case
Best Case

Multiples Across Competitors

OGN Competitors Multiples
Organon & Co Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Organon & Co
NYSE:OGN
2.5B USD 0.4 5.1 6.3 7.8
US
Eli Lilly and Co
NYSE:LLY
1T USD 16.9 54.7 36.7 39.3
US
Johnson & Johnson
NYSE:JNJ
529.7B USD 5.6 19.8 13.8 16.9
CH
Roche Holding AG
SIX:ROG
277.3B CHF 4.5 29.4 12.5 14.6
UK
AstraZeneca PLC
LSE:AZN
210.9B GBP 4.9 30.4 19.8 28.9
CH
Novartis AG
SIX:NOVN
222B CHF 5 19.5 15.6 20.2
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK 5.6 17.1 11.9 13.8
US
Merck & Co Inc
NYSE:MRK
269.1B USD 4.2 14.1 10 11.9
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 344.9 865
US
Pfizer Inc
NYSE:PFE
145.8B USD 2.3 14.8 7.5 10.3
FR
Sanofi SA
PAR:SAN
96.9B EUR 1.5 7.1 6.4 6.4
P/E Multiple
Earnings Growth PEG
US
Organon & Co
NYSE:OGN
Average P/E: 21.2
5.1
7%
0.7
US
Eli Lilly and Co
NYSE:LLY
54.7
54%
1
US
Johnson & Johnson
NYSE:JNJ
19.8
6%
3.3
CH
Roche Holding AG
SIX:ROG
29.4
29%
1
UK
AstraZeneca PLC
LSE:AZN
30.4
38%
0.8
CH
Novartis AG
SIX:NOVN
19.5
17%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
17.1
2%
8.6
US
Merck & Co Inc
NYSE:MRK
14.1
14%
1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.8
27%
0.5
FR
Sanofi SA
PAR:SAN
7.1
25%
0.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Organon & Co
NYSE:OGN
Average EV/EBITDA: 44.1
6.3
5%
1.3
US
Eli Lilly and Co
NYSE:LLY
36.7
34%
1.1
US
Johnson & Johnson
NYSE:JNJ
13.8
2%
6.9
CH
Roche Holding AG
SIX:ROG
12.5
5%
2.5
UK
AstraZeneca PLC
LSE:AZN
19.8
10%
2
CH
Novartis AG
SIX:NOVN
15.6
6%
2.6
DK
Novo Nordisk A/S
CSE:NOVO B
11.9
1%
11.9
US
Merck & Co Inc
NYSE:MRK
10
6%
1.7
IE
E
Endo International PLC
LSE:0Y5F
344.9
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
0%
N/A
FR
Sanofi SA
PAR:SAN
6.4
8%
0.8
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Organon & Co
NYSE:OGN
Average EV/EBIT: 94.1
7.8
7%
1.1
US
Eli Lilly and Co
NYSE:LLY
39.3
37%
1.1
US
Johnson & Johnson
NYSE:JNJ
16.9
6%
2.8
CH
Roche Holding AG
SIX:ROG
14.6
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
28.9
23%
1.3
CH
Novartis AG
SIX:NOVN
20.2
12%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
13.8
0%
N/A
US
Merck & Co Inc
NYSE:MRK
11.9
8%
1.5
IE
E
Endo International PLC
LSE:0Y5F
865
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
7%
1.5
FR
Sanofi SA
PAR:SAN
6.4
15%
0.4